AREVA Med, now known as Orano Med, is pioneering the development of Targeted Alpha Therapy (TAT) utilizing lead-212 (212Pb), a potent alpha-emitting radioisotope. This innovative approach aims to create targeted therapies for various cancers by leveraging the unique properties of 212Pb, which is known for its effectiveness in delivering therapeutic payloads directly to cancer cells. The company has established a diverse pipeline of 212Pb-labeled compounds, including AlphaMedix™, which targets neuroendocrine tumors through somatostatin receptor binding. The promising results from clinical trials, including a 67% objective response rate in initial studies, highlight the potential of these therapies in treating challenging cancer types.

To support its ambitious therapeutic goals, Orano Med has developed a robust industrial platform for the large-scale production of 212Pb. This platform is built on a patented chemical process that ensures high purity and cost-effective production, utilizing thorium-232 as a raw material source. The company operates facilities in both France and the United States, including the Laboratoire Maurice Tubiana and the Alpha Therapy Laboratory, which are dedicated to producing 212Pb and its conjugated drugs for clinical trials and commercial use. This integrated approach not only addresses the supply challenges associated with alpha-emitting radioisotopes but also positions Orano Med as a leader in the rapidly growing field of radioligand therapy.

United States

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. 

Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

AREVA Med

Company Details